Deficient spindle assembly checkpoint in multiple myeloma

PLoS ONE

Volumn 6, Issue 11, 2011, Pages

  Díaz Rodríguez, Elena ^a   Álvarez Fernández, Stela ^a   Chen, Xi ^a   Paiva, Bruno ^a,b   López Pérez, Ricardo ^a   García Hernández, Juan Luis ^a,b   San Miguel, Jesús F ^a,b   Pandiella, Atanasio ^a  

^a UNIVERSITY OF SALAMANCA   (Spain)

^b HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CELL CYCLE PROTEIN 20; PROTEIN MAD2; RNA; CALCIUM BINDING PROTEIN; CELL CYCLE PROTEIN; MAD2L1 PROTEIN, HUMAN; MESSENGER RNA; NOCODAZOLE; REPRESSOR PROTEIN;

ANEUPLOIDY; ARTICLE; CANCER CELL CULTURE; CELL GROWTH; CHROMOSOME SEGREGATION; CHROMOSOME STRUCTURE; CONTROLLED STUDY; MICROTUBULE; MULTIPLE MYELOMA; PROTEIN CONTENT; SPINDLE ASSEMBLY CHECKPOINT; DRUG EFFECT; GENE EXPRESSION REGULATION; GENETIC TRANSDUCTION; GENETICS; GENOMIC INSTABILITY; HUMAN; M PHASE CELL CYCLE CHECKPOINT; METABOLISM; PATHOLOGY; RETROVIRUS; TUMOR CELL LINE;

ANEUPLOIDY; CALCIUM-BINDING PROTEINS; CELL CYCLE PROTEINS; CELL LINE, TUMOR; GENE EXPRESSION REGULATION, NEOPLASTIC; GENOMIC INSTABILITY; HUMANS; M PHASE CELL CYCLE CHECKPOINTS; MULTIPLE MYELOMA; NOCODAZOLE; REPRESSOR PROTEINS; RETROVIRIDAE; RNA, MESSENGER; TRANSDUCTION, GENETIC;

EID: 84859247463     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0027583     Document Type: Article

References (41)

1. Jemal A, Siegel R, Ward E, Murray T, Xu J, et al. (2007) Cancer statistics, 2007. CA Cancer J Clin 57: 43-66.
2. Raab MS, Podar K, Breitkreutz I, Richardson PG, Anderson KC, (2009) Multiple myeloma. Lancet 374: 324-339.
3. Ocio EM, Mateos MV, Maiso P, Pandiella A, San-Miguel JF, (2008) New drugs in multiple myeloma: mechanisms of action and phase I/II clinical findings. Lancet Oncol 9: 1157-1165.
4. Gutierrez NC, Garcia-Sanz R, San Miguel JF, (2007) Molecular biology of myeloma. Clin Transl Oncol 9: 618-624.
5. Kuehl WM, Bergsagel PL, (2002) Multiple myeloma: evolving genetic events and host interactions. Nat Rev Cancer 2: 175-187.
6. Chng WJ, Fonseca R, (2009) Centrosomes and myeloma; aneuploidy and proliferation. Environ Mol Mutagen 50: 697-707.
7. Fonseca R, Blood E, Rue M, Harrington D, Oken MM, et al. (2003) Clinical and biologic implications of recurrent genomic aberrations in myeloma. Blood 101: 4569-4575.
8. Bergsagel PL, Kuehl WM, (2005) Molecular pathogenesis and a consequent classification of multiple myeloma. J Clin Oncol 23: 6333-6338.
9. Amiel A, Goldzak G, Gaber E, Yosef G, Fejgin MD, et al. (2005) Random aneuploidy and telomere capture in chronic lymphocytic leukemia and chronic myeloid leukemia patients. Cancer Genet Cytogenet 163: 12-16.
10. Ho PJ, Campbell LJ, Gibson J, Brown R, Joshua D, (2002) The biology and cytogenetics of multiple myeloma. Rev Clin Exp Hematol 6: 276-300.
11. Sawyer JR, (2011) The prognostic significance of cytogenetics and molecular profiling in multiple myeloma. Cancer Genet 204: 3-12.
12. Bharadwaj R, Yu H, (2004) The spindle checkpoint, aneuploidy, and cancer. Oncogene 23: 2016-2027.
13. Kops GJ, Weaver BA, Cleveland DW, (2005) On the road to cancer: aneuploidy and the mitotic checkpoint. Nat Rev Cancer 5: 773-785.
14. Diaz-Rodriguez E, Sotillo R, Schvartzman JM, Benezra R, (2008) Hec1 overexpression hyperactivates the mitotic checkpoint and induces tumor formation in vivo. Proc Natl Acad Sci U S A 105: 16719-16724.
15. Shepard JL, Amatruda JF, Finkelstein D, Ziai J, Finley KR, et al. (2007) A mutation in separase causes genome instability and increased susceptibility to epithelial cancer. Genes Dev 21: 55-59.
16. Sotillo R, Hernando E, Diaz-Rodriguez E, Teruya-Feldstein J, Cordon-Cardo C, et al. (2007) Mad2 overexpression promotes aneuploidy and tumorigenesis in mice. Cancer Cell 11: 9-23.
17. Weaver BA, Silk AD, Montagna C, Verdier-Pinard P, Cleveland DW, (2007) Aneuploidy acts both oncogenically and as a tumor suppressor. Cancer Cell 11: 25-36.
18. Wassmann K, Benezra R, (2001) Mitotic checkpoints: from yeast to cancer. Curr Opin Genet Dev 11: 83-90.
19. Schvartzman JM, Sotillo R, Benezra R, (2010) Mitotic chromosomal instability and cancer: mouse modelling of the human disease. Nat Rev Cancer 10: 102-115.
20. Evans RP, Naber C, Steffler T, Checkland T, Maxwell CA, et al. (2008) The selective Aurora B kinase inhibitor AZD1152 is a potential new treatment for multiple myeloma. Br J Haematol 140: 295-302.
21. Gorgun G, Calabrese E, Hideshima T, Ecsedy J, Perrone G, et al. (2011) A novel Aurora-A kinase inhibitor MLN8237 induces cytotoxicity and cell-cycle arrest in multiple myeloma. Blood 115: 5202-5213.
22. Hose D, Reme T, Meissner T, Moreaux J, Seckinger A, et al. (2009) Inhibition of aurora kinases for tailored risk-adapted treatment of multiple myeloma. Blood 113: 4331-4340.
23. Negri JM, McMillin DW, Delmore J, Mitsiades N, Hayden P, et al. (2009) In vitro anti-myeloma activity of the Aurora kinase inhibitor VE-465. Br J Haematol 147: 672-676.
24. Shi Y, Reiman T, Li W, Maxwell CA, Sen S, et al. (2007) Targeting aurora kinases as therapy in multiple myeloma. Blood 109: 3915-3921.
25. Stewart HJ, Kishikova L, Powell FL, Wheatley SP, Chevassut TJ, (2011) The polo-like kinase inhibitor BI 2536 exhibits potent activity against malignant plasma cells and represents a novel therapy in multiple myeloma. Exp Hematol 39: 330-338.
26. Carvajal-Vergara X, Tabera S, Montero JC, Esparis-Ogando A, Lopez-Perez R, et al. (2005) Multifunctional role of Erk5 in multiple myeloma. Blood 105: 4492-4499.
27. Ma MH, Yang HH, Parker K, Manyak S, Friedman JM, et al. (2003) The proteasome inhibitor PS-341 markedly enhances sensitivity of multiple myeloma tumor cells to chemotherapeutic agents. Clin Cancer Res 9: 1136-1144.
28. DuBridge RB, Tang P, Hsia HC, Leong PM, Miller JH, et al. (1987) Analysis of mutation in human cells by using an Epstein-Barr virus shuttle system. Mol Cell Biol 7: 379-387.
29. Diaz-Rodriguez E, Pandiella A, (2010) Multisite phosphorylation of Erk5 in mitosis. J Cell Sci 123: 3146-3156.
30. Kung AL, Sherwood SW, Schimke RT, (1990) Cell line-specific differences in the control of cell cycle progression in the absence of mitosis. Proc Natl Acad Sci U S A 87: 9553-9557.
31. Sudakin V, Chan GK, Yen TJ, (2001) Checkpoint inhibition of the APC/C in HeLa cells is mediated by a complex of BUBR1, BUB3, CDC20, and MAD2. J Cell Biol 154: 925-936.
32. Pandiella A, Carvajal-Vergara X, Tabera S, Mateo G, Gutierrez N, et al. (2003) Imatinib mesylate (STI571) inhibits multiple myeloma cell proliferation and potentiates the effect of common antimyeloma agents. Br J Haematol 123: 858-868.
33. Carro A, Rico D, Rueda OM, Diaz-Uriarte R, Pisano DG, (2010) waviCGH: a web application for the analysis and visualization of genomic copy number alterations. Nucleic Acids Res 38: W182-187.
34. Livak KJ, Schmittgen TD, (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25: 402-408.
35. Carrasco DR, Tonon G, Huang Y, Zhang Y, Sinha R, et al. (2006) High-resolution genomic profiles define distinct clinico-pathogenetic subgroups of multiple myeloma patients. Cancer Cell 9: 313-325.
36. Dobles M, Liberal V, Scott ML, Benezra R, Sorger PK, (2000) Chromosome missegregation and apoptosis in mice lacking the mitotic checkpoint protein Mad2. Cell 101: 635-645.
37. Michel L, Diaz-Rodriguez E, Narayan G, Hernando E, Murty VV, et al. (2004) Complete loss of the tumor suppressor MAD2 causes premature cyclin B degradation and mitotic failure in human somatic cells. Proc Natl Acad Sci U S A 101: 4459-4464.
38. Hernando E, Nahle Z, Juan G, Diaz-Rodriguez E, Alaminos M, et al. (2004) Rb inactivation promotes genomic instability by uncoupling cell cycle progression from mitotic control. Nature 430: 797-802.
39. Schliekelman M, Cowley DO, O'Quinn R, Oliver TG, Lu L, et al. (2009) Impaired Bub1 function in vivo compromises tension-dependent checkpoint function leading to aneuploidy and tumorigenesis. Cancer Res 69: 45-54.
40. Bolanos-Garcia VM, Blundell TL, (2011) BUB1 and BUBR1: multifaceted kinases of the cell cycle. Trends Biochem Sci 36: 141-150.
41. Wang X, Sinn AL, Pollok K, Sandusky G, Zhang S, et al. (2010) Preclinical activity of a novel multiple tyrosine kinase and aurora kinase inhibitor, ENMD-2076, against multiple myeloma. Br J Haematol 150: 313-325.